Key Highlights

  • Aethlon Medical shares settled up 14% at $2.47.
  • The company's fiscal first-quarter loss narrowed 12% to $1.55 million, mostly from lower operating spend.
  • Cash stood at $4.93 million.
  • Aethlon dosed the first patient in the final cohort of its Phase 1 oncology study of the Hemopurifier.

Aethlon Medical, Inc. (NASDAQ: AEMD) shares settled up 14% at $2.47 after the company's fiscal first-quarter loss narrowed 12% to $1.55 million, mostly due to lower operating spend, with cash of $4.93 million.

What Happened

The company also dosed the first patient in the final cohort of its Phase 1 oncology study of the Hemopurifier, a device that filters blood to remove extracellular vesicles and viral or tumor cargo. Early biomarker notes included shifts in extracellular vesicles and immune-function markers.

Market Reaction

Shares rose on the combination of a narrower quarterly loss and the trial progress, though the reported cash position of $4.93 million remains a short runway relative to funding a full registration program.

Outlook

Completion of the final Phase 1 cohort without safety issues, along with whether observed immune or extracellular vesicle changes are large enough to support a Phase 2 design, represents the next disclosed milestones for Aethlon Medical.